IceCure Medical Ltd. (NASDAQ:ICCM) Receives $52.50 Consensus PT from Analysts

Shares of IceCure Medical Ltd. (NASDAQ:ICCM) have been given a consensus recommendation of “Hold” by the five analysts that are presently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation and three have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $52.50.

Several research firms have weighed in on ICCM. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IceCure Medical in a research report on Friday, July 17th. Zacks Research downgraded IceCure Medical from a “hold” rating to a “strong sell” rating in a report on Friday, August 14th. Finally, Wall Street Zen upgraded shares of IceCure Medical from a “sell” rating to a “hold” rating in a report on Saturday, September 5th.

IceCure Medical Price Performance

Shares of NASDAQ ICCM opened at $2.21 on Friday. The stock has a market capitalization of $7.58 million, a price-to-earnings ratio of -0.26 and a beta of 0.45. The business has a 50-day moving average of $2.93 and a 200-day moving average of $7.61. IceCure Medical has a fifty-two week low of $2.06 and a fifty-two week high of $42.00.

IceCure Medical (NASDAQ:ICCM) last released its earnings results on Tuesday, June 30th. The company reported ($1.60) earnings per share (EPS) for the quarter. IceCure Medical had a negative net margin of 427.67% and a negative return on equity of 174.26%. The company had revenue of $0.91 million during the quarter. On average, sell-side analysts expect that IceCure Medical will post -4.61 EPS for the current year.

Institutional Investors Weigh In On IceCure Medical

A hedge fund recently bought a new stake in IceCure Medical stock. Jane Street Group LLC purchased a new position in shares of IceCure Medical Ltd. (NASDAQ:ICCM) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 109,638 shares of the company’s stock, valued at approximately $67,000. Jane Street Group LLC owned 0.16% of IceCure Medical as of its most recent filing with the Securities & Exchange Commission. 0.62% of the stock is currently owned by institutional investors and hedge funds.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.